Novartis slots PhI cardiovascular candidate into pipeline, paying Korean partner $80M upfront
Novartis is plucking a Phase I small molecule candidate out of Korea that it believes can treat a variety of diseases — including certain cardiovascular conditions …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.